GC
SRPT icon

Guidance Capital’s Sarepta Therapeutics SRPT Stock Holding History

Guidance Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,822
Closed -$212K – 204
2024
Q4 		$212K Sell
1,822
-47
-3% -$5.76K 0.06% 188
2024
Q3 		$238K Sell
1,869
-8
-0.4% -$1.11K 0.07% 169
2024
Q2 		$267K Sell
1,877
-133
-7% -$17.1K 0.09% 157
2024
Q1 		$238K Sell
2,010
-1
-0% -$122 0.09% 161
2023
Q4 		$194K Buy
2,011
+44
+2% +$4.22K 0.08% 170
2023
Q3 		$237K Buy
1,967
+42
+2% +$4.75K 0.11% 135
2023
Q2 		$208K Buy
+1,925
New +$248K 0.09% 147

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Guidance Capital's SRPT Position: Q1 2025 in Review

Guidance Capital sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 1,822 shares — an estimated $212K sold.

Guidance Capital first reported a position in SRPT in Q2 2023 and held it in 7 quarters. The position peaked at $267K in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Guidance Capital reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Guidance Capital sold 1,822 Sarepta Therapeutics shares in Q1 2025, an estimated $212K.
  • Guidance Capital first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 7 quarters.
  • Guidance Capital's Sarepta Therapeutics position peaked at $267K in Q2 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Guidance Capital's 13F filing for Q1 2025, filed 6 May 2025.